Preparedness and capability — not market access — increasingly determine which organizations can compete in today’s trade ...

For the first time in its 16-year analysis of the pharma industry, Deloitte found obesity drugs are the largest contributor ...

Deloitte Ghana has successfully concluded its Earth Month celebrations with an award ceremony, highlighting a year-long journey of nurturing sustainability within the workplace.The event, held in ...

TFI International (NYSE:TFII) held its 2026 annual meeting of shareholders by telephone on April 27, with Chairman, President ...

The sixteenth annual "Measuring the Return from Pharmaceutical Innovation" report shows projected internal rate of return ...

AI has transformed finance, yet execution still hinges on human authority and accountability. The next shift needs to move humans from approvals to strategic oversight.

Five years ago, underwriting a mixed-use deal took a commercial real estate analyst more than a week. Today, an agentic AI ...

For decades, executives have asked the same question: how do we win, serve and retain the customer? The answer is about to be ...

GLP-1s overtake oncology drugs as obesity treatments lead late-stage pharma pipeline value, reshaping drug development and investment strategies.

A Deloitte survey found that 80% of manufacturing executives plan to allocate at least 20% of their improvement budgets in ...

At a pivotal moment for Sri Lanka’s Knowledge and Innovation sector, Deloitte Sri Lanka recently shared key insights at a ...

While GLP-1 drugs for weight loss and diabetes have become transformative for both patients and health systems, it comes with ...